Literature DB >> 10853848

Combined use of exhaled nitric oxide and airway hyperresponsiveness in characterizing asthma in a large population survey.

A H Henriksen1, T Lingaas-Holmen, M Sue-Chu, L Bjermer.   

Abstract

The aim of the present study was to see whether measurements of airway hyperresponsiveness (AHR) and nitric oxide (NO) in exhaled air (ENO) either separately or in combination, could differentiate between asthmatics and healthy control subjects in a population based survey. In central Norway 8,571 adolescents participated in a large-scale epidemiological survey (Young Helseundersøkelsen i Nord-Trøndelag (Health Survey in North-Trøndelag; HUNT). Asthmatic symptoms when exposed to pollen, pets or house-dust were reported by 7.8% (suspected asthmatics), while 56% reported no asthmatic or allergic symptoms (control subjects). From these respective groups 151 and 213 adolescents were investigated with allergy screening, measurements of exhaled and nasal NO, and methacholine challenge test. AHR (provocative dose of methacholine causing a 20% fall in forced expiratory volume in one second (PD20) <2 mg) was confirmed in 75% of the suspected asthmatics versus 25% of the control subjects, whereas 52% versus 20% had elevated levels of ENO (> or =8 parts per billion (ppb)). ENO and dose response ratio to methacholine (DRR) were positively correlated (r=0.41, p<0.001). ENO was significantly elevated in atopic versus nonatopic suspected asthmatics (11.7 ppb and 5.6 ppb respectively, p<0.001). Suspected asthmatics with both AHR and atopy had the highest levels of ENO (14.2 ppb). It is concluded that measurements of nitric oxide in exhaled air alone are not a useful tool in diagnosing asthma in population surveys, but that the combination of airway hyperresponsiveness and elevated nitric oxide in exhaled air is a very specific finding for allergic asthma. The use of dose response ratio to methacholine did not provide any additional information to the provocative dose of methacholine causing a 20% fall in forced expiratory volume in one second in this study.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10853848     DOI: 10.1034/j.1399-3003.2000.15e07.x

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  8 in total

1.  Exhaled nitric oxide levels in atopic children: relation to specific allergic sensitisation, AHR, and respiratory symptoms.

Authors:  J D Leuppi; S H Downs; S R Downie; G B Marks; C M Salome
Journal:  Thorax       Date:  2002-06       Impact factor: 9.139

2.  Increase in exhaled nitric oxide (eNO) after work-related isocyanate exposure.

Authors:  L Barbinova; X Baur
Journal:  Int Arch Occup Environ Health       Date:  2006-01-19       Impact factor: 3.015

Review 3.  Exhaled nitric oxide measurements: clinical application and interpretation.

Authors:  D R Taylor; M W Pijnenburg; A D Smith; J C De Jongste
Journal:  Thorax       Date:  2006-09       Impact factor: 9.139

4.  Exhaled nitric oxide, susceptibility and new-onset asthma in the Children's Health Study.

Authors:  T M Bastain; T Islam; K T Berhane; R S McConnell; E B Rappaport; M T Salam; W S Linn; E L Avol; Y Zhang; F D Gilliland
Journal:  Eur Respir J       Date:  2010-07-15       Impact factor: 16.671

5.  Exhaled nitric oxide and asthma: complex interactions between atopy, airway responsiveness, and symptoms in a community population of children.

Authors:  P J Franklin; S W Turner; P N Le Souëf; S M Stick
Journal:  Thorax       Date:  2003-12       Impact factor: 9.139

Review 6.  Exhaled nitric oxide in the clinical management of asthma.

Authors:  Chitra Dinakar
Journal:  Curr Allergy Asthma Rep       Date:  2004-11       Impact factor: 4.919

7.  Subjects in a Population Study with High Levels of FENO Have Associated Eosinophil Airway Inflammation.

Authors:  Gerdt C Riise; Kjell Torén; Anna-Carin Olin
Journal:  ISRN Allergy       Date:  2011-03-02

Review 8.  Measurements of fractional exhaled nitric oxide in pediatric asthma.

Authors:  Youn-Soo Hahn
Journal:  Korean J Pediatr       Date:  2013-10-31
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.